Blog
-
Acasti Pharmaceuticals update – market finally wakes up to the potential implications of Phase 3 trials of CaPre
It has been quite the month for holders of Acasti Pharmaceuticals as the chart below pays testimony to. The stock has risen from just over $1 to a peak of $2.50 in recent days. Full background coverage by us can be found on the stock HERE. Acasti is one of our largest positions and was […]
-
PATHFINDER MINERALS AGM UPDATE
It seems that there has been a collective disbelief amongst PFP shareholders in the now likely outcome to the dialogue of recent months with General Veloso post yesterday’s AGM. As an attendee we have been asked to comment on that meet. Firstly, the resolution (8) that was voted down was the disapplication of pre-emption rights. […]
-
Shefa Gems – Bulk sampling results confirm investment case
By Dr. Michael Green Good progress continues towards mining and revenue generation at Shefa Gems. In late-June, Shefa completed the bulk sampling of Kishon Mid-Reach Zone 2, and the results are expected to expand the deposit base of the company’s 100%-owned multi-gemstone project in Northern Israel. By way of an introduction, Shefa Gems has a […]